Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients

NCT03172377 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT03172377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients
Lead sponsor
Radboud University Medical Center
Phase
Phase 4
Overall status
Unknown status
Start date
May 3, 2017
Completion date
October 31, 2022
Enrollment
174 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, crohn disease in remission